To address the unmet needs of a diverse patient population, we’ve developed unique AI-supported drug discovery methods that accurately identify oncogenic yet untargeted mutations, then match them to potential drug candidates in a tumor-agnostic fashion.
Our approach is supported by our proprietary technology platform, Foresight. Foresight recapitulates hundreds of naturally occurring mutations in-vitro and monitors their effect on signaling pathway activity, in order to predict their oncogenicity and their response to experimental compounds.
Our lead program focuses on FORE-8394, an investigational drug identified by our platform for its inhibitory effect across a wide range of unique BRAF mutations.
Fore is backed by top investors with deep
knowledge and experience in company formation.
